Latest Breaking News On - Mjamesf howard - Page 1 : comparemela.com

argenx SE: argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression in generalized myasthenia.

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including mini.

FDA Approves Zilbrysq for Myasthenia Gravis

Zilbrysq (zilucoplan) is the first self-administered treatment for myasthenia gravis. Rapid symptom improvements were observed in clinical trials.

FDA Approves Complement C5 Inhibitor Zilucoplan for Myasthenia Gravis

With the approval, zilucoplan becomes the first once-daily subcutaneous complement C5 inhibitor available for adults with generalized myasthenia gravis.